Pactiv Evergreen Q4 Sales $1.53B Beat $1.45B Estimate

Pactiv Evergreen (NASDAQ:PTVE) reported quarterly sales of $1.53 billion which beat the analyst consensus estimate of $1.45 billion by 5.31 percent. This is a 29.96 percent increase over sales of $1.18 billion the same

byBenzinga Newsdesk

February 23, 2022

1 minute read

Uxin Registers 57% Revenue Growth In Q3 Backed By Solid Transaction Volume

By Anusuya Lahiri

Today, 7:54 PM

Chinese online used car dealer Uxin Ltd (NASDAQ:UXIN) reported third-quarter FY22 revenue growth of 56.9% year-on-year to $79.5 million (RMB506.6 million). The…

UXIN

Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of The Nanobody Sonelokimab In Patients With Active Psoriatic Arthritis

By Bill Haddad

Today, 7:54 PM

MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody® sonelokimab in active psoriatic arthritis Expected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab

MLTX

Microsoft Finds Apple Gatekeeper’s ‘Achilles’ Heel That Lets Threat Actors Bypass Security Checks

By Ananya Gairola

Today, 7:54 PM

Microsoft Corporation (NASDAQ: MSFT) shared a macOS security flaw, dubbed Achilles, with Apple Inc. (NASDAQ: AAPL). The vulnerability has been fixed now.

AAPL